{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:47:06Z","timestamp":1793450826179,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007957","name":"Chongqing Municipal Education Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007957","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ejmech.2023.115141","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T11:20:26Z","timestamp":1674472826000},"page":"115141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Synthesis and evaluation of N-sulfonylpiperidine-3-carboxamide derivatives as capsid assembly modulators inhibiting HBV in vitro and in HBV-transgenic mice"],"prefix":"10.1016","volume":"249","author":[{"given":"Jiaxin","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongqi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieli","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefei","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0377-877X","authenticated-orcid":false,"given":"Luyi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115141_bib1","doi-asserted-by":"crossref","first-page":"S303","DOI":"10.1053\/j.gastro.2004.09.045","article-title":"Prevention of hepatitis B virus-related hepatocellular carcinoma","volume":"127","author":"Lok","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2023.115141_bib2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/17460441.2017.1255195","article-title":"The current status and future directions of hepatitis B antiviral drug discovery","volume":"12","author":"Tang","year":"2017","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115141_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113780","article-title":"Design, synthesis and evaluation of heteroaryldihydropyrimidine analogues bearing spiro ring as hepatitis B virus capsid protein inhibitors","volume":"225","author":"Ma","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115141_bib4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1053\/j.gastro.2018.07.057","article-title":"Development of direct-acting antiviral and host-targeting agents for treatment of hepatitis B virus infection","volume":"156","author":"Xia","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2023.115141_bib5","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1093\/jac\/dkr388","article-title":"Nucleoside\/nucleotide analogues in the treatment of chronic hepatitis B","volume":"66","author":"Fung","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2023.115141_bib6","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1002\/hep.22956","article-title":"Benefits and risks of interferon therapy for hepatitis B","volume":"49","author":"Perrillo","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2023.115141_bib7","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1872-034X.2011.00921.x","article-title":"Treatment of chronic hepatitis B with nucleos(t)ide analogues","volume":"42","author":"Ohishi","year":"2012","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.ejmech.2023.115141_bib8","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1128\/jvi.66.7.4107-4116.1992","article-title":"The arginine-rich domain of the hepatitis B virus core protein is required for pregenome encapsidation and productive viral positive-strand DNA synthesis but not for virus assembly","volume":"66","author":"Nassal","year":"1992","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2023.115141_bib9","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.antiviral.2015.06.020","article-title":"Core protein: a pleiotropic keystone in the HBV lifecycle","volume":"121","author":"Zlotnick","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2023.115141_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2017.05.003","article-title":"Role of hepatitis B core protein in HBV transcription and recruitment of histone acetyltransferases to cccDNA minichromosome","volume":"144","author":"Chong","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2023.115141_bib11","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2023.115141_bib12","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1126\/science.1077215","article-title":"Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids","volume":"299","author":"Deres","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2023.115141_bib13","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3851\/IMP2152","article-title":"In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations","volume":"17","author":"Wang","year":"2012","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.ejmech.2023.115141_bib14","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01463-20","article-title":"Preclinical profile and characterization of the hepatitis B virus core protein inhibitor ABI-H0731","volume":"64","author":"Huang","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2023.115141_bib15","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/j.gastro.2017.10.017","article-title":"Efficacy of NVR 3-778, alone and in combination with pegylated interferon, vs entecavir in uPA\/SCID mice with humanized livers and HBV infection","volume":"154","author":"Klumpp","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2023.115141_bib16","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.1021\/acs.jmedchem.8b00654","article-title":"Synthesis and evaluation of N-Phenyl-3-sulfamoyl-benzamide derivatives as capsid assembly modulators inhibiting hepatitis B virus (HBV)","volume":"61","author":"Vandyck","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115141_bib17","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.antiviral.2007.06.014","article-title":"The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging","volume":"76","author":"Feld","year":"2007","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2023.115141_bib18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.coph.2016.08.004","article-title":"Modulators of HBV capsid assembly as an approach to treating hepatitis B virus infection","volume":"30","author":"Cole","year":"2016","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115141_bib19","doi-asserted-by":"crossref","first-page":"7651","DOI":"10.1021\/acs.jmedchem.6b00879","article-title":"Design and synthesis of orally bioavailable 4-methyl heteroaryldihydropyrimidine based hepatitis B virus (HBV) capsid inhibitors","volume":"59","author":"Qiu","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115141_bib20","article-title":"Heteroaryldihydropyrimidine (HAP) and sulfamoylbenzamide (SBA) inhibit hepatitis B virus replication by different molecular mechanisms","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2023.115141_bib21","article-title":"Structure-based discovery of N-Sulfonylpiperidine-3-Carboxamides as novel capsid assembly modulators for potent inhibition of HBV replication","volume":"14","author":"Yang","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2023.115141_bib22","series-title":"Characterization of a Novel Capsid Assembly Modulator for the Treatment of Chronic Hepatitis B Virus Infection","author":"Burdette","year":"2022"},{"key":"10.1016\/j.ejmech.2023.115141_bib23","article-title":"Preclinical characterization of ABI-H2158, an HBV core inhibitor with dual mechanisms of action","volume":"209","author":"Yan","year":"2022","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2023.115141_bib24","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00082-18","article-title":"Preclinical profile of AB-423, an inhibitor of hepatitis B virus pregenomic RNA encapsidation","volume":"62","author":"Mani","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2023.115141_bib25","article-title":"Novel hepatitis B virus capsid assembly modulator induces potent antiviral responses in vitro and in humanized mice","volume":"64","author":"Amblard","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2023.115141_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2021.105211","article-title":"Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein","volume":"197","author":"Mani","year":"2022","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2023.115141_bib27","doi-asserted-by":"crossref","first-page":"6066","DOI":"10.1021\/acs.jmedchem.0c00292","article-title":"Discovery of (1H-Pyrazolo[3,4-c]pyridin-5-yl)sulfonamide analogues as hepatitis B virus capsid assembly modulators by conformation constraint","volume":"63","author":"Wang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115141_bib28","article-title":"Oxadiazepinone HBV capsid assembly modulators","author":"Kuduk","year":"2021","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2023.115141_bib29","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00835-18","article-title":"Novel potent capsid assembly modulators regulate multiple steps of the hepatitis B virus life cycle","volume":"62","author":"Lahlali","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2023.115141_bib30","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1128\/AAC.41.8.1715","article-title":"Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication","volume":"41","author":"Ladner","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2023.115141_bib31","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00560-17","article-title":"Capsid assembly modulators have a dual mechanism of action in primary human hepatocytes infected with hepatitis B virus","volume":"61","author":"Berke","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2023.115141_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010057","article-title":"Amino acid residues at core protein dimer-dimer interface modulate multiple steps of hepatitis B virus replication and HBeAg biogenesis","volume":"17","author":"Liu","year":"2021","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ejmech.2023.115141_bib33","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/1743-422X-6-226","article-title":"Nuclease-resistant double-stranded DNA controls or standards for hepatitis B virus nucleic acid amplification assays","volume":"6","author":"Meng","year":"2009","journal-title":"Virol. J."},{"key":"10.1016\/j.ejmech.2023.115141_bib34","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s13238-014-0041-4","article-title":"A new unconventional HLA-A2-restricted epitope from HBV core protein elicits antiviral cytotoxic T lymphocytes","volume":"5","author":"Sun","year":"2014","journal-title":"Protein Cell"},{"key":"10.1016\/j.ejmech.2023.115141_bib35","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1080\/22221751.2019.1584018","article-title":"Hepatitis B virus mutation pattern rtL180M+A181C+M204V may contribute to entecavir resistance in clinical practice","volume":"8","author":"Liu","year":"2019","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.ejmech.2023.115141_bib36","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01734-18","article-title":"Preclinical characterization of NVR 3-778, a first-in-class capsid assembly modulator against hepatitis B virus","volume":"63","author":"Lam","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2023.115141_bib37","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1128\/JCM.01073-09","article-title":"Selection and counterselection of the rtI233V adefovir resistance mutation during antiviral therapy","volume":"48","author":"Schildgen","year":"2010","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.ejmech.2023.115141_bib38","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/jvh.13397","article-title":"Characterization of Hepatitis B virus polymerase mutations A194T and CYEI and tenofovir disoproxil fumarate or tenofovir alafenamide resistance","volume":"28","author":"Liu","year":"2021","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.ejmech.2023.115141_bib39","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1002\/hep4.2095","article-title":"Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB-506 from Phase 1 studies in healthy subjects and those with hepatitis B","volume":"6","author":"Yuen","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.ejmech.2023.115141_bib40","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S2468-1253(21)00176-X","article-title":"Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial","volume":"6","author":"Yuen","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ejmech.2023.115141_bib41","series-title":"Safety, Pharmacokinetics, and Antiviral Activity of ABI-H2158, a Hepatitis B Virus Core Inhibitor: a Randomized, Placebo-Controlled Phase 1 Study","author":"Agarwal","year":"2022"},{"key":"10.1016\/j.ejmech.2023.115141_bib42","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2022.05.027","article-title":"Safety and efficacy of vebicorvir administered with entecavir in treatment-naive patients with chronic hepatitis B virus infection","volume":"77","author":"Sulkowski","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2023.115141_bib43","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.antiviral.2017.11.006","article-title":"APOBEC3B edits HBV DNA and inhibits HBV replication during reverse transcription","volume":"149","author":"Chen","year":"2018","journal-title":"Antivir. Res."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423000569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423000569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T11:14:32Z","timestamp":1737285272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423000569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":43,"alternative-id":["S0223523423000569"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115141","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and evaluation of N-sulfonylpiperidine-3-carboxamide derivatives as capsid assembly modulators inhibiting HBV in vitro and in HBV-transgenic mice","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115141","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115141"}}